Skip to main content

Table 2 Association between AAPR and NAFLD in different models

From: The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population

 

HR (95%CI) P-value

Crude model

Model 1

Model 2

Model 3

Model 4

AAPR

0.26 (0.20, 0.33) < 0.0001

0.41 (0.31, 0.53) < 0.0001

0.52 (0.40, 0.69) < 0.0001

0.54 (0.41, 0.72) < 0.0001

0.61 (0.47, 0.81) 0.0004

AAPR (Quintile)

 Q1

Ref

Ref

Ref

Ref

Ref

 Q2

0.80 (0.70, 0.91) 0.0005

0.81 (0.72, 0.93) 0.0017

0.89 (0.78, 1.02) 0.0874

0.90 (0.79, 1.02) 0.0999

0.91 (0.80, 1.04) 0.1490

 Q3

0.67 (0.59, 0.77) < 0.0001

0.73 (0.64, 0.83) < 0.0001

0.82 (0.71, 0.94) 0.0045

0.83 (0.72, 0.95) 0.0075

0.85 (0.74, 0.98) 0.026

 Q4

0.52 (0.45, 0.60) < 0.0001

0.61 (0.53, 0.71) < 0.0001

0.68 (0.58, 0.79) < 0.0001

0.66 (0.57, 0.77) < 0.0001

0.73 (0.63, 0.85) < 0.0001

 Q5

0.47 (0.40, 0.55) < 0.0001

0.59 (0.84, 0.90) < 0.0001

0.67 (0.57, 0.78) < 0.0001

0.63 (0.53, 0.74) < 0.0001

0.72 (0.61, 0.85) < 0.0001

P-trend

< 0.0001

< 0.0001

< 0.0001

< 0.0001

< 0.0001

  1. Abbreviations: CI Confidence interval, HR Hazard ratios, AAPR Albumin-to-alkaline phosphatase ratio
  2. Crude model adjusted for none; model 1 adjusted for sex, age, height, BMI and SBP; model adjusted for model 1 plus liver function markers (GGT, ALT, AST, GLB, TP); model 3 adjusted for model 2 plus blood glucose metabolism marker FPG and kidney function marker Cr; model 4 adjusted model 3 plus lipid metabolic markers (TG, HDL-C, LDL-C)
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X